Double coordination-driven Fe-DOX synergy enhances ferroptosis and immunogenic cancer therapy
Related Experiment Video
Updated: Oct 29, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
Published on: March 15, 2024
Gaeun Ma1, Yun-Hwa Jeong2, Yeonsu Ryu1
1Department of Applied Life Science, BK21 Program, Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, Republic of Korea.
Abstract:
Ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, has emerged as a potential therapeutic strategy for cancer. However, intrinsic resistance, off-target toxicity, and poor redox efficiency limit the effectiveness of existing ferroptosis-inducing platforms. This study reports novel heparin-derived metal coordination nanoparticles (HDMC NP) that leverage catechol-metal-drug coordination chemistry to enhance ferroptosis and immunogenic cell death (ICD). In this self-assembled supramolecular system, doxorubicin (DOX) directly coordinates to Fe3+ centers established by catechol-Fe3+ interactions on the heparin backbone, forming a stable HDMC NP with high drug-loading efficiency. This coordination not only stabilizes the complex under neutral conditions but also triggers disassembly in response to pH changes in the tumor microenvironment. Notably, the DOX-Fe3+ pairing supports sustained redox activity, amplifying ROS production and ferroptotic stress in a coordination-dependent manner beyond the effect of either component alone. In animal models, HDMC NP suppresses tumor growth by inducing both ferroptosis and ICD, characterized by calreticulin exposure and CD8+ T cell infiltration. Collectively, this platform provides a redox-active nanotherapeutic based on coordination-defined assembly with potential for broad applications in metal-ion modulated diseases.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...